<DOC>
	<DOCNO>NCT00891553</DOCNO>
	<brief_summary>The purpose study determine whether bone mineral density increase subgroup postmenopausal osteoporotic woman study CR9108963 , 6 12 month follow cessation ronacaleret therapy .</brief_summary>
	<brief_title>CR9112792 , Follow-up Study CR9108963</brief_title>
	<detailed_description>CR9112792 follow-up study CR9108963 , 12 month dose range study ronacaleret ( SB-751689 ) , calcium sense receptor antagonist , postmenopausal woman osteoporosis . CR9108963 evaluate effect ronacaleret ( 100mg , 200mg , 300mg , 400mg ) bone mineral density ( BMD ) , safety tolerability comparison placebo 2 active comparators , alendronate teriparatide . CR9108963 terminate earlier plan due observe lack efficacy lumbar spine hip BMD . In study follow-up subject 6 12 month discontinue treatment ronacaleret evaluate potential mineralization bone follow cessation ronacaleret therapy . Subjects pre-specified site CR9108963 placebo , 200mg , 300mg 400mg dose group include study .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Informed consent : Subject willing able provide write informed consent . Subjects : Subjects must complete Month 12 visit study CR9108963 , early withdrawal visit Month 10 visit . DXA : Subjects must either final evaluable spine hip DXA scan CR9108963 confirm Synarc , take within 4 week last dose study medication . Study medication : Subjects must placebo ronacaleret 200mg , 300mg 400mg â‰¥299 day study CR9108963 . Any treatment PTHbased therapy strontium ranelate discontinuation treatment study CR9108963 . Chronic systemic corticosteroid [ e.g. , glucocorticoid , mineralocorticoid ] treatment 2 intraarticular injection within past year use oral , parenteral , longterm , highdose inhaled corticosteroid . Treatment topical corticosteroid exclude subject participate . Treatment topical corticosteroid exclude subject participation . Treatment fluoride ( dose great 10mg/day ) osteoporosis discontinuation treatment study CR9108963 . Administration investigational drug discontinuation treatment study CR9108963 . Subject , opinion investigator , unfit study unable comply requirement protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>bone mineral density</keyword>
	<keyword>calcium-sensing receptor antagonist</keyword>
	<keyword>ronacaleret</keyword>
	<keyword>postmenopausal osteoporosis</keyword>
</DOC>